Evidence map›Paper›PMID 41575867›Full record

ArticleACS infectious diseases2026

Using Next Generation Chemiluminescent Probes to Improve the

Angela Hellingman, Nele Lara Göttle, Annabelle Walz, Nicolas Michel Beat Brancucci, Sergio Wittlin, Pascal Mäser, Matthias Rottmann

Abstract read
In one paragraph

Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Angela HellingmanSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.ORCID 0009-0001-3686-1203
Nele Lara GöttleSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Annabelle WalzSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Nicolas Michel Beat BrancucciSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.
Sergio WittlinSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.ORCID 0000-0002-0811-0912
Pascal MäserSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.ORCID 0000-0003-3122-1941
Matthias RottmannSwiss Tropical and Public Health Institute, 4123 Allschwil, Switzerland.ORCID 0000-0002-2207-7899

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria remains a major global health threat, and the emergence of partial artemisinin resistance challenges current treatment regimens. Reliable antimalarial screening assays are therefore essential for identifying new drug candidates. The parasite reduction ratio (PRR) assay provides valuable pharmacodynamic insights but is limited by its labor-intensive, 14- to 28-day incubation period. We developed an optimized PRR assay protocol using the highly sensitive chemiluminescence-based

Indexed as

AntimalarialsLuminescent MeasurementsPlasmodium falciparumHumansMalaria, FalciparumParasitic Sensitivity TestsAntimalarialsAquaSparkchemiluminescencemalariaoptimizationP. falciparumPRR assay

Identifiers

PMID41575867
PMCPMC12910577

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.